tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

Takeda Pharmaceutical Co Ltd

TAK
๎˜น
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
18.040USD
+0.180+1.01%
์ข…๊ฐ€ย 03/24, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
56.99B์‹œ๊ฐ€์ด์•ก
78.54P/E TTM
๎™

Takeda Pharmaceutical Co Ltd

18.040
+0.180+1.01%
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

+1.01%

5์ผ

-1.90%

1๊ฐœ์›”

-3.27%

6๊ฐœ์›”

+20.59%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+15.72%

1๋…„

+20.19%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

TradingKey Takeda Pharmaceutical Co Ltd ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-03-23

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Takeda Pharmaceutical Co Ltd์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•ˆ์ •์  ์ƒํƒœ์ด๋ฉฐ, ESG ๊ณต์‹œ๋Š” ์—…๊ณ„๋ฅผ ์„ ๋„ํ•˜๋Š” ์ˆ˜์ค€์ž…๋‹ˆ๋‹ค.์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—…์—์„œ 157๊ฐœ ์ค‘ 44์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 20.13์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์ƒ์Šน ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ํ‰๋ฒ”ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ๊ณผ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋Š” ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Takeda Pharmaceutical Co Ltd ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
44 / 157
์ „์ฒด ์ˆœ์œ„
123 / 4546
์‚ฐ์—…
์ œ์•ฝ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
์ค‘๋ฆฝ

Takeda Pharmaceutical Co Ltd ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
๋†’์€ ๋ฐฐ๋‹น๊ธˆ
ํšŒ์‚ฌ๋Š” ๋†’์€ ๋ฐฐ๋‹น๊ธˆ์„ ์ง€๊ธ‰ํ•˜๋Š” ํšŒ์‚ฌ๋กœ, ์ตœ์‹  ๋ฐฐ๋‹น๊ธˆ ์ง€๊ธ‰ ๋น„์œจ์€ 287.84%์ž…๋‹ˆ๋‹ค.
์•ˆ์ •์ ์ธ ๋ฐฐ๋‹น๊ธˆ
ํšŒ์‚ฌ๋Š” ์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ •๊ธฐ์ ์œผ๋กœ ๋ฐฐ๋‹น๊ธˆ์„ ์ง€๊ธ‰ํ•˜์˜€์œผ๋ฉฐ, ์ตœ์‹  ๋ฐฐ๋‹น๊ธˆ ์ง€๊ธ‰ ๋น„์œจ์€ 287.84%์ž…๋‹ˆ๋‹ค.
๊ณผ๋Œ€ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ 77.76๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋†’์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 84.00M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 5.04% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
Mairs and Power๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž Mairs and Power์ด(๊ฐ€) ์ด ์ฃผ์‹ 17.58K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

3 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
20.133
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+12.92%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Takeda Pharmaceutical Co Ltd ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

Takeda Pharmaceutical Co Ltd ์ •๋ณด๎˜

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
์ข…๋ชฉ ์ฝ”๋“œ TAK
ํšŒ์‚ฌTakeda Pharmaceutical Co Ltd
CEOWeber (Christophe)
์›น์‚ฌ์ดํŠธhttps://www.takeda.com/
KeyAI
๎™